DNA vaccine containing Flagellin A gene induces significant immune responses against Helicobacter pylori infection: An in vivo study

Document Type : Original Article


1 Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

2 Department of Biotechnology, Islamic Azad University of Ahvaz, Ahvaz Branch, Ahvaz, Iran

3 Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

4 Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran


Objective(s): Helicobacter pylori is one of the most prevalent human infectious agents that is directly involved in various upper digestive tract diseases. Although antibiotics-based therapy and proton pump inhibitors eradicate the bacteria mostly, their effectiveness has been declined recently due to emergence of antibiotic-resistant strains. Development of a DNA vaccine is a promising approach against bacterial pathogens. Genes encoding motility factors are promising immunogens to develop a DNA vaccine against H. pylori infection due to critical role of these genes in bacterial attachment and colonization within the gastric lumen. The present study aimed to synthesize a DNA vaccine construct based on the Flagellin A gene (flaA), the predominant flagellin subunit in H. pylori flagella.
Materials and Methods: The coding sequence of flaA was amplified through PCR and sub-cloned in the pBudCE4.1 vector. The recombinant vector was introduced into the human dermal fibroblast cells, and its potency to express the flaA protein was analyzed using SDS-PAGE. The recombinant construct was intramuscularly (IM) injected into the mice, and the profiles of cytokines and immunoglobulins were measured using ELISA.
Results: It has been found that flaA was successfully expressed in cells. Recombinant-vector also increased the serum levels of evaluated cytokines and immunoglobulins in mice.
Conclusion: These findings showed that the pBudCE4.1-flaA construct was able to activate the immune responses. This study is the first step towards synthesis of recombinant-construct based on the flaA gene. Immunization with such construct may inhibit the H. pylori-associated infection; however, further experiments are urgent.


1. Ang TL, Fock KM. Clinical epidemiology of gastric cancer. Singapore Med J 2014;55:621-628.
2. Crabtree JE, Wessler S. Special Issue “H. pylori Virulence Factors in the Induction of Gastric Cancer”. Toxins 2018;10:176.
3. Atherton JC, Blaser MJ. Coadaptation of Helicobacter pylori and humans: ancient history, modern implications. J Clin Invest 2009;119:2475-2487.
4.    Hooi JK, Lai WY, Ng WK, Suen MM, Underwood FE, Tanyingoh D, et al. Global prevalence of Helicobacter pylori infection: systematic review and meta-analysis. Gastroenterology 2017;153:420-429.
5. Konno M, Fujii N, Yokota S-i, Sato K, Takahashi M, Sato K, et al. Five-year follow-up study of mother-to-child transmission of Helicobacter pylori infection detected by a random amplified polymorphic DNA fingerprinting method. J Clin Microbiol 2005;43:2246-2250.
6. Benoit SL, Miller EF, Maier RJ. Helicobacter pylori stores nickel to aid its host colonization. Infect Immun 2013;81:580-584.
7. Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VE. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol 2014;20:12753-12766.
8.    Abadi ATB. Strategies used by helicobacter pylori to establish persistent infection. World J Gastroenterol 2017;23:2870-2882.
9.    Israel DA, Peek RM. Mechanisms of Helicobacter pylori-induced gastric inflammation. In: Said HM. editor. Physiology of the Gastrointestinal Tract. 6th Ed. Elsevier; 2018. p. 1517-1545.
10.    Hernández-Hernández LdC, Lazcano-Ponce EC, López-Vidal Y, Aguilar-Gutiérrez GR. Relevance of Helicobacter pylori virulence factors for vaccine development. salud Publica Mex 2009; 51:s447-s454.
11.    Svennerholm A-M, Lundgren A. Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol 2007; 50:146-156.
12.    Del Giudice G, Malfertheiner P, Rappuoli R. Development of vaccines against Helicobacter pylori. Expert Rev Vaccines 2009; 8:1037-1049.
13.    Michetti P. Vaccine against Helicobacter pylori: Fact or fiction? Gut 1997;41:728-730.
14.    Agarwal K, Agarwal S. Helicobacter pylori vaccine: from past to future. In: Nath KA editor. Mayo Clinic Proceedings. Elsevier; 2008.p. 169-175.
15.    Skene C, Young A, Every A, Sutton P. Helicobacter pylori flagella: antigenic profile and protective immunity. FEMS Immunol Med Microbiol 2007;50:249-256.
16.    Abadi ATB. Vaccine against Helicobacter pylori: Inevitable approach. World J Gastroenterol 2016; 22:3150-3157.
17.    Jiang Z, Tao X-H, Huang A-L, Wang P-L. A study of recombinant protective Helicobacter pylori antigens. World J Gastroenterol 2002; 8:308-311.
18.    Gu H. Role of Flagella in the Pathogenesis of Helicobacter pylori. Curr Microbioly 2017;74: 863-869.
19.    Yan J, Liang S-H, Mao Y-F, Li L-W, Li S-P. Construction of expression systems for flaA and flaB genes of Helicobacter pylori and determination of immunoreactivity and antigenicity of recombinant proteins. World J Gastroenterol 2003; 9:2240-2250.
20.    Spohn G, Scarlato V. Motility, chemotaxis, and flagella. In: Mobley HLT, Mendz GL,  Hazell SL. editors. Helicobacter pylori: Physiology and Genetics. Wiley Online Library 2001. p. 239-248.
21. Green MR, Russell DW. Isolation of High-Molecular-Weight DNA Using Organic Solvents. Cold Spring Harb Protoc. 2017; 356-360.
22.    Sambrook J, Russell DW. Preparation and transformation of competent E. coli using calcium chloride, In Molecular cloning: a laboratory manual, third ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 2000. p.1.116-1.118.
24.    Georgopoulos SD, Papastergiou V, Karatapanis S. Helicobacter pylori eradication therapies in the era of increasing antibiotic resistance: a paradigm shift to improved efficacy. Gastroenterol Res Pract 2012; Special Issue:1-9.
25.    Blaser MJ, Berg DE. Helicobacter pylori genetic diversity and risk of human disease. J Clin Invest 2001;107:767-773.
26.    Debraekeleer A, Remaut H. Future perspective for potential Helicobacter pylori eradication therapies. Future Microbiol 2018;13:671-687.
27.    Burkitt MD, Duckworth CA, Williams JM, Pritchard DM. Helicobacter pylori-induced gastric pathology: insights from in vivo and ex vivo models. Dis Model Mech 2017;10:89-104.
28.    Keeney KM, Yurist-Doutsch S, Arrieta M-C, Finlay BB. Effects of antibiotics on human microbiota and subsequent disease. Annu Rev Microbiol 2014;68:217-235.
29.    Moss SF. The clinical evidence linking Helicobacter pylori to gastric cancer. Cell Mol Gastroenterol Hepatol 2017;3:183-191.
30.    Arora S, Czinn SJ. Vaccination as a method of preventing Helicobacter pylori–associated gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1890-1891.
31.    Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine 2019;37:7295-7299.
32.    Vega AE, Cortiñas TI, Mattana CM, Silva HJ, de Centorbi OP. Growth of Helicobacter pylori in medium supplemented with cyanobacterial extract. J Clin Microbiol 2003;41:5384-5388.
33.    Coban C, Kobiyama K, Aoshi T, Takeshita F, Horii T, Akira S, et al. Novel strategies to improve DNA vaccine immunogenicity. Curr Gene Ther 2011;11:479-484.
34.    Stenler S, Blomberg P, Smith CE. Safety and efficacy of DNA vaccines: Plasmids vs. minicircles. Hum Vaccin Immunother 2014;10:1306-1308.
35.    Ottemann KM, Lowenthal AC. Helicobacter pylori uses motility for initial colonization and to attain robust infection. Infection and immunity 2002;70:1984-1990.
36.    Eaton K, Suerbaum S, Josenhans C, Krakowka S. Colonization of gnotobiotic piglets by Helicobacter pylori deficient in two flagellin genes. Infect Immun 1996;64:2445-2448.
37.    Zarei M, Mosayebi G, Khansarinejad B, Abtahi H. Antigenic and immunogenic evaluation of Helicobacter pylori FlaA epitopes. Iran J Basic Med Sci 2017;20:920-926.
38.    Hajam IA, Dar PA, Shahnawaz I, Jaume JC, Lee JHJE. Bacterial flagellin—a potent immunomodulatory agent. Exp Mol Med 2017;49:e373-e388.
39.    Cui B, Liu X, Fang Y, Zhou P, Zhang Y, Wang YJErov. Flagellin as a vaccine adjuvant. Expert Rev Vaccines 2018;17:335-349.
40.    Lindholm C, Quiding-Järbrink M, Lönroth H, Hamlet A, Svennerholm A-M. Local cytokine response in Helicobacter pylori-infected subjects. Infect Immun 1998;66:5964-5971.
41.    Bagheri N, Salimzadeh L, Shirzad H. The role of T helper 1-cell response in Helicobacter pylori-infection. Microb Pathog 2018;123;1-8.
42.    Romagnani S. Type 1 T helper and type 2 T helper cells: functions, regulation and role in protection and disease. Int J Clin Lab Res 1992;21:152-158.
43.    Rudnicka W, Jarosinska A, Bak-Romaniszyn L, Moran A, Planeta-Malecka I, Wadstrom T, et al. Helicobacter pylori lipopolysaccharide in the IL-2 milieu activates lymphocytes from dyspeptic children. FEMS Immun Med Microbiol 2003;36:141-145.
44.    Nurgalieva ZZ, Conner ME, Opekun AR, Zheng CQ, Elliott SN, Ernst PB, et al. B-cell and T-cell immune responses to experimental Helicobacter pylori infection in humans. Infect Immun 2005;73:2999-3006.
45.    She RC, Wilson AR, Litwin CM. Evaluation of Helicobacter pylori immunoglobulin G (IgG), IgA, and IgM serologic testing compared to stool antigen testing. Clin Vaccine Immunol 2009;16:125-135.
46.    Sutton P, Boag JM. Status of vaccine research and development for Helicobacter pylori. Vaccine 2019;37:7295-7299.
47.    Moss SF, Moise L, Lee DS, Kim W, Zhang S, Lee J, et al. HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine 2011;29:2085-2091.
48.    Lina TT, Alzahrani S, Gonzalez J, Pinchuk IV, Beswick EJ, Reyes VEJWjogW. Immune evasion strategies used by Helicobacter pylori. World J Gastroenterol 2014;20:1275-12766.
49.    Telford JL, Ghiara P, Dell’Orco M, Comanducci M, Burroni D, Bugnoli M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994;179:1653-1658.
50.    Xiang Z, Censini S, Bayeli PF, Telford JL, Figura N, Rappuoli R, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995;63:94-98.
51.   Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 1995;92:6499–6503
52. Stadtlander CTKH, Gangemi JD, Khanolvar SS, Kitsos CM, Farris HE Jr., Fulton LK, et al. Immunogenicity and safety of recombinant Helicobacter pylori urease in a nonhuman primate. Dig Dis Sci1996;41:1853–1862.